Technical Analysis for NEO - NeoGenomics, Inc.

Grade Last Price % Change Price Change
grade A 36.31 0.55% 0.20
NEO closed up 0.55 percent on Thursday, July 9, 2020, on 67 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Jul 28
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical NEO trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
New 52 Week Closing High Bullish 0.55%
NR7 Range Contraction 0.55%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company's trademarks include NeoFISH, NeoFlow, NeoSITE, NeoArray, NeoType, and MelanoSITE. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Cancer Biology Diseases Genetics Medical Tests Lymphoma Leukemia Anatomical Pathology Laboratory Techniques Solid Tumor Cancers Bladder Cancer Hybridization Cytogenetics Fluorescence In Situ Hybridization

Is NEO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 36.8
52 Week Low 18.52
Average Volume 1,239,319
200-Day Moving Average 27.17
50-Day Moving Average 28.64
20-Day Moving Average 30.27
10-Day Moving Average 32.64
Average True Range 1.42
ADX 24.43
+DI 38.98
-DI 9.85
Chandelier Exit (Long, 3 ATRs ) 32.53
Chandelier Exit (Short, 3 ATRs ) 29.94
Upper Bollinger Band 36.81
Lower Bollinger Band 23.73
Percent B (%b) 0.96
BandWidth 43.23
MACD Line 2.10
MACD Signal Line 1.29
MACD Histogram 0.8087
Fundamentals Value
Market Cap 2.88 Billion
Num Shares 79.4 Million
EPS -0.33
Price-to-Earnings (P/E) Ratio -110.03
Price-to-Sales 2.72
Price-to-Book 4.01
PEG Ratio 3.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.66
Resistance 3 (R3) 37.67 37.24 37.44
Resistance 2 (R2) 37.24 36.89 37.23 37.36
Resistance 1 (R1) 36.77 36.68 37.01 36.76 37.28
Pivot Point 36.34 36.34 36.45 36.33 36.34
Support 1 (S1) 35.87 35.99 36.11 35.86 35.34
Support 2 (S2) 35.44 35.78 35.43 35.26
Support 3 (S3) 34.97 35.44 35.19
Support 4 (S4) 34.96